GT Biopharma Inc (GTBP) Stock AnalysisGTBPGT Biopharma Inc

GT Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary Tri-specific Killer Engager (TriKE) natural killer (NK) cell engager platform. Its TriKE platform is designed to harness and enhance the cancer-killing abilities of a patient’s immune system’s natural killer cells. Its product candidate pipeline includes GTB-3550, GTB-3650, GTB-5550, GTB-7550, GTB-6550, GTB-1050, and other product candidates. GTB-3550 is a TriKE comprised of two single-chain variable fragments (scFv) composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. GTB-3650 is a TriKE which targets CD33 on the surface of myeloid leukemias. The Company also has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

GT Biopharma Inc is not a good buy right now due to a significant net loss of $28.4 million for FY2025 and a current RSI of 23.39, indicating oversold conditions but also potential ongoing weakness. The stock has dropped 78.26% year-to-date, reflecting severe market challenges and investor sentiment issues.